https://www.selleckchem.com/pr....oducts/liraglutide.h
5 A g-1 after 50 cycles and 1017.6 mAh g-1 at 2 A g-1 after 200 cycles, remarkably outperforming commercial Si material. With a low-cost precursor and facile approach, this work provides a new strategy for the synthesis of a commercial high-capacity Si anode. Anlotinib is a new multi-target tyrosine kinase inhibitor (TKI) and has been shown to have antitumor effects and synergistic antitumor effects with immunotherapy only in animal studies and in the 2nd-line treatment in small clinical trials. A real-world study with large sample
Curtir
Comentario
Compartilhar
